on CNS Pharmaceuticals, Inc. (NASDAQ:CNSP)
CNS Pharmaceuticals Announces Virtual Analyst & Investor Day
CNS Pharmaceuticals, Inc., a biopharmaceutical company focused on developing treatments for brain and central nervous system cancers, will host a Virtual Analyst & Investor Day on December 11, 2024. The event will feature discussions led by renowned experts in Glioblastoma Multiforme (GBM), an aggressive brain cancer with no cure and an average survival rate of 14 to 16 months post-diagnosis.
The session will include insights from CNS Pharmaceuticals' executives alongside Key Opinion Leaders such as Prof. Dr. Michael Weller, Dr. Samuel Goldlust, and Dr. Erin Dunbar. They will discuss GBM, the development of the company's drug Berubicin, and strategies for their second asset, TPI 287. The webcast will be available on the company's website, with a replay accessible for 90 days.
R. H.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all CNS Pharmaceuticals, Inc. news